Decaux Olivier
CHU de Rennes, service de médecine interne, hôpital Sud, Rennes, France. Faculté de médecine de Rennes, université Rennes-1, Rennes, France.
Rev Prat. 2018 Sep;68(7):777-784.
Conduct in case of monoclonal gammapathy ? Monoclonal gammopathies are frequent in general population (about 3 % beyond 50 years) and their prevalence increases with age. They may be associated with malignant haemopathy (multiple myeloma for IgG and IgA, Waldenström disease for IgM). In absence of malignant haemopathy, the diagnosis is that of monoclonal gammopathy of indeterminate significance (MGUS). MGUS accounts for the majority (over 60 %) cases of monoclonal gammopathy. Only patients with multiple myeloma or Waldenström disease require treatment. For MGUS, smoldering myeloma and smoldering Waldenström disease, therapeutic abstention is recommended but regular and prolonged monitoring is necessary given the risk of progression to malignant hemopathy. Given the prevalence of monoclonal gammopathies in general population and the frequency of MGUS, it is rational to limit initial explorations in asymptomatic patients.
单单克隆丙种球蛋白病的处理?单克隆丙种球蛋白病在普通人群中很常见(50岁以上人群中约为3%),且其患病率随年龄增长而增加。它们可能与恶性血液病有关(IgG和IgA型为多发性骨髓瘤,IgM型为华氏巨球蛋白血症)。在没有恶性血液病的情况下,诊断为意义未明的单克隆丙种球蛋白病(MGUS)。MGUS占单克隆丙种球蛋白病病例的大多数(超过60%)。只有多发性骨髓瘤或华氏巨球蛋白血症患者需要治疗。对于MGUS、冒烟型骨髓瘤和冒烟型华氏巨球蛋白血症,建议暂不治疗,但鉴于有进展为恶性血液病的风险,需要进行定期且长期的监测。鉴于单克隆丙种球蛋白病在普通人群中的患病率以及MGUS的发生率,对无症状患者限制初始检查是合理的。